Continuous Subcutaneous Insulin Infusion Market Size & Growth Forecast 2027–2036, By Segments (Patient Type, Product, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Continuous Subcutaneous Insulin Infusion Market size was over USD 810.6 million in 2026 and is likely to grow at a 8.55% CAGR between 2027 and 2036, exceeding USD 1.84 billion by 2036. The industry revenue for 2027 is calculated at USD 868.96 million.
Get more details on this report
Request Free Sample ReportContinuous Subcutaneous Insulin Infusion Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 41.55% share in 2026, supported by established diabetes care pathways, widespread insulin pump adoption, and integrated patient monitoring and follow-up across specialist clinics.
- Asia Pacific is projected to grow at a 10.28% CAGR as access to diabetes care improves, insulin pump availability expands, and more patients adopt technology-enabled insulin delivery.
Segment Momentum
- Diabetes Type 1 leads with a 78% share due to continuous insulin dependence and strong alignment with pump-based therapy for precise basal and bolus dosing in routine management.
- Patch Pumps are growing fastest due to demand for discreet, wearable, and tubing-free designs that improve convenience, mobility, and ease of use compared with traditional insulin delivery systems.
Market Expansion Drivers
- Rising global diabetes prevalence increasing demand for advanced insulin delivery systems.
- Integration of AI-enabled insulin pumps and CGM systems improving glycemic control.
- Expanding geriatric population driving adoption of automated diabetes management technologies.
Leading Market Participants
- Key companies in the continuous subcutaneous insulin infusion market include Medtronic plc (Ireland), Insulet Corporation (United States), Roche Holding AG (Switzerland), Ypsomed Holding AG (Switzerland), B. Braun SE (Germany), CeQur SA (Switzerland), Tandem Diabetes Care, Inc. (United States), SOOIL Development Co., Ltd. (South Korea).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 810.6 million
- 2027 Estimated Market Size: USD 868.96 million.
- Projected Market Size: USD 1.84 billion by 2036
- Growth Forecast: 8.55% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Diabetes Type 1 (Patient Type) | Tethered Pumps (Product) | Hospitals & Clinics (End Use)
- Emerging Opportunity Segment: Diabetes Type 2 (Patient Type) | Patch Pumps (Product) | Homecare (End Use)
Market Growth Drivers and Industry Trends
Rising global diabetes prevalence increasing demand for advanced insulin delivery systems
The growing prevalence of diabetes is strengthening demand for more effective and convenient insulin management approaches, which will drive the continuous subcutaneous insulin infusion market growth. As the number of individuals requiring regular insulin therapy increases, patients and healthcare providers are placing greater emphasis on delivery systems that can provide consistent dosing while reducing the complexity associated with multiple daily injections. Insulin infusion technologies can support more flexible diabetes management by enabling continuous delivery and individualized dosing adjustments, making them increasingly relevant for patients seeking improved treatment convenience and greater control over daily glucose management.
Integration of AI-enabled insulin pumps and CGM systems improving glycemic control
Integration of artificial intelligence with insulin pumps and continuous glucose monitoring technologies is enhancing automated decision-making in diabetes care, thereby propelling the continuous subcutaneous insulin infusion market growth. AI-enabled systems can analyze glucose patterns, recognize changes in insulin requirements, and support more responsive dosing decisions when connected with real-time monitoring devices. This integration reduces the burden of manually interpreting glucose readings and adjusting therapy, while closed-loop capabilities can help maintain glucose levels within desired ranges and provide patients with a more streamlined approach to ongoing diabetes management.
Expanding geriatric population driving adoption of automated diabetes management technologies
The expanding elderly population, which often requires long-term and carefully monitored diabetes care, will boost the continuous subcutaneous insulin infusion market demand as automated technologies become more important for simplifying treatment routines. Older adults may face challenges associated with frequent glucose monitoring, insulin administration, and complex dosing schedules, increasing interest in systems that automate portions of these tasks. Pump-based delivery combined with glucose monitoring can reduce the need for repeated manual interventions and support caregivers and healthcare professionals in managing therapy, particularly when consistent insulin administration is important for maintaining stable glucose levels.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global diabetes prevalence increasing demand for advanced insulin delivery systems | 2.50% | High | North America, Asia Pacific | High | Near Term |
| Integration of AI-enabled insulin pumps and CGM systems improving glycemic control | 2.00% | High | North America, Europe | High | Mid Term |
| Expanding geriatric population driving adoption of automated diabetes management technologies | 1.50% | High | Global | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the continuous subcutaneous insulin infusion market, accounting for 41.55% in 2026. The region's strong position is supported by the high prevalence of diabetes, established healthcare infrastructure, and broad adoption of advanced insulin delivery technologies. Greater patient awareness of intensive diabetes management, increasing preference for automated and convenient treatment options, and integration of insulin pumps with glucose monitoring systems are strengthening demand. Favorable reimbursement environments, specialist diabetes care, and continued investment in connected medical devices further support the region's established market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to be the fastest-growing region, driven by the expanding diabetes burden, improving access to specialized healthcare, and rising awareness of advanced insulin management solutions. Healthcare infrastructure development across emerging economies is creating greater opportunities for insulin pump adoption, while increasing healthcare expenditure and broader availability of diabetes monitoring technologies are improving patient access. Growing clinician familiarity with pump-based therapy and a gradual shift toward technology-enabled chronic disease management are also expected to accelerate regional adoption.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Structured diabetes care systemsIn Germany, continuous subcutaneous insulin infusion market activity is shaped by structured chronic disease management programs. Germany emphasizes clinically guided insulin pump adoption, with demand supported by reimbursement-backed healthcare pathways and strong physician-led diabetes care protocols.
France 🇫🇷
Reimbursement-supported adoptionIn France, continuous subcutaneous insulin infusion market activity is influenced by reimbursement-driven access to advanced diabetes therapies. France prioritizes clinically validated insulin pump systems within public healthcare pathways for long-term disease management.
Italy 🇮🇹
Specialist-led insulin therapyIn Italy, continuous subcutaneous insulin infusion market demand is shaped by specialist-driven diabetes care practices. Italy focuses on gradual adoption of insulin pump technologies supported by hospital endocrinology departments and patient-centered chronic care models.
Japan 🇯🇵
Precision diabetes managementIn Japan, continuous subcutaneous insulin infusion market demand reflects precision-focused diabetes care in an aging population. Japan prioritizes advanced insulin delivery systems that support tight glycemic control and long-term disease stability under specialist supervision.
South Korea 🇰🇷
Digital diabetes monitoring growthIn South Korea, continuous subcutaneous insulin infusion market demand is supported by expanding digital health adoption and improved diabetes diagnostics. South Korea emphasizes connected insulin delivery systems integrated with mobile monitoring and hospital-based care networks.
United States 🇺🇸
Diabetes tech adoption leadershipIn the U.S., continuous subcutaneous insulin infusion market demand is driven by strong adoption of advanced diabetes management technologies. The U.S. prioritizes insulin pump integration with digital monitoring systems, with uptake supported by specialist endocrinology care and reimbursement structures enabling long-term chronic disease management.
Segment Leadership and Growth Trends
Continuous Subcutaneous Insulin Infusion Market Share (%), by Patient Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportPatient Type Segment Analysis: Diabetes Type 1 (Largest Segment) vs Diabetes Type 2 (Fastest-Growing Segment)
Diabetes type 1 represented the largest patient segment in the continuous subcutaneous insulin infusion market, accounting for 78% share in 2026. Continuous insulin delivery is particularly relevant for individuals requiring intensive and consistent insulin management, supporting the established use of infusion systems within type 1 diabetes care. Increasing emphasis on precise glucose management, individualized insulin delivery, and improved day-to-day disease management continues to support adoption among this patient population. Greater awareness of advanced insulin delivery approaches and ongoing improvements in diabetes management practices further reinforce the segment's leading position.
Diabetes type 2 is the fastest-growing patient segment as the role of advanced insulin delivery technologies expands beyond traditional intensive insulin therapy populations. Growing recognition of individualized treatment strategies and the need for improved glucose management can encourage selected type 2 patients to consider continuous infusion approaches. Broader awareness of connected diabetes technologies, increasing focus on treatment adherence, and greater personalization of insulin management are supporting wider consideration of continuous subcutaneous insulin infusion in this patient group.
Product Segment Analysis: Tethered Pumps (Largest Segment) vs Patch Pumps (Fastest-Growing Segment)
Tethered pumps held the largest share of 74.4% in 2026 in the continuous subcutaneous insulin infusion market, reflecting their established use for controlled and continuous insulin delivery. These systems provide structured insulin administration through an external pump connected to the infusion site, enabling patients to adjust therapy according to their individual requirements. Their established clinical familiarity, integration into diabetes management routines, and ability to support precise insulin delivery continue to sustain demand for tethered systems.
Patch pumps are experiencing the fastest growth as patients and healthcare providers increasingly seek more discreet and convenient insulin delivery options. Their compact, wearable design can reduce the practical burden associated with conventional pump configurations and may support greater flexibility during daily activities. Increasing interest in patient-centric diabetes technologies, simplified device handling, and less intrusive insulin delivery is encouraging adoption of patch-based systems.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Patient Type | Diabetes Type 1, Diabetes Type 2 | Diabetes Type 1 | Diabetes Type 2 |
| Product | Patch Pumps, Tethered Pumps | Tethered Pumps | Patch Pumps |
| End Use | Hospitals & Clinics, Homecare, Laboratories | Hospitals & Clinics | Homecare |
Competitive Landscape and Market Positioning
Key companies in the continuous subcutaneous insulin infusion market:
1. Medtronic plc (Ireland)
2. Insulet Corporation (United States)
3. Roche Holding AG (Switzerland)
4. Ypsomed Holding AG (Switzerland)
5. B. Braun SE (Germany)
6. CeQur SA (Switzerland)
7. Tandem Diabetes Care Inc. (United States)
8. SOOIL Development Co. Ltd. (South Korea)
The continuous subcutaneous insulin infusion market is evolving rapidly with advancements in automated insulin delivery systems and connected diabetes management technologies. Manufacturers are emphasizing user-friendly wearable devices, AI-supported glucose monitoring integration, and personalized insulin delivery algorithms to improve treatment outcomes. Rising adoption of remote healthcare solutions is also strengthening innovation in diabetes care platforms.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Medtronic plc (Ireland) | |||||||
| Insulet Corporation (United States) | |||||||
| Roche Holding AG (Switzerland) | |||||||
| Ypsomed Holding AG (Switzerland) | |||||||
| B. Braun SE (Germany) | |||||||
| CeQur SA (Switzerland) | |||||||
| Tandem Diabetes Care Inc. (United States) | |||||||
| SOOIL Development Co. Ltd. (South Korea). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Abbott & Medtronic | Aug-24 | The companies announced a global partnership to integrate Abbott’s FreeStyle Libre CGM sensor technology with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems. This collaboration aims to provide a seamless, integrated diabetes management solution, pairing Abbott's sensing technology with Medtronic's advanced insulin delivery algorithms. |
| F. Hoffmann-La Roche Ltd | Jul-24 | The company received CE Mark certification for the Accu-Chek SmartGuide, an AI-enabled continuous glucose monitoring (CGM) system. Designed for patients 18 and older with type 1 or type 2 diabetes on flexible insulin therapy, the system provides real-time glucose readings and predictive alerts to help users manage their condition and prevent hypoglycemia. |
| Medtronic | Sep-23 | The company received CE Mark approval for its Simplera continuous glucose monitor (CGM). This all-in-one, disposable device features a simple, two-step insertion process and a 50% smaller profile compared to previous sensors, significantly enhancing convenience and reducing the environmental impact of diabetes monitoring equipment. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Continuous Subcutaneous Insulin Infusion Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Connectivity | Non-Connected Pumps, Bluetooth-Connected Pumps, Smartphone-Integrated Pumps |
| Reimbursement Coverage | Fully Reimbursed, Partially Reimbursed, Self-Pay |
| Purchasing Channel | Direct Sales, Specialty Distributors, Retail and Pharmacy Channels |
Continuous Subcutaneous Insulin Infusion Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Insulin Pump Reimbursement and Patient Access Assessment |
|
| Connected Diabetes Ecosystem Analysis |
|
| Patient Journey and Therapy Adherence Insights |
|
Need a different cut of the data?
Request Custom ResearchHow large is the continuous subcutaneous insulin infusion market?
What is the expected industry size of continuous subcutaneous insulin infusion by 2036?
How is rising diabetes prevalence influencing the shift toward pump-based insulin delivery in the continuous subcutaneous insulin infusion market?
How are AI-enabled pump-CGM integration and aging patient needs shaping adoption patterns in insulin infusion systems?
Why does Diabetes Type 1 dominate the continuous insulin infusion market?
Why are Patch Pumps the fastest-growing product segment in insulin infusion systems?
What makes North America the largest continuous subcutaneous insulin infusion market?
Why is Asia Pacific experiencing rapid growth in the continuous subcutaneous insulin infusion market?
Who holds a significant market share in the continuous subcutaneous insulin infusion landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization